News & Events

Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation

Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Harpreet Singh: A New Benchmark for KRAS G12C Targeted Therapy in NSCLC

Harpreet Singh: A New Benchmark for KRAS G12C Targeted Therapy in NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Can Precision Medicine Crack Another KRAS Code? New Study Targets a Rare Lung Cancer Mutation-but the Clinical Test Still Lies Ahead

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC

Divarasib Outperforms First-Gen Competitors in Pretreated KRAS G12C NSCLC